SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $11,571.12 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 2,376 shares of the business’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total value of $11,571.12. Following the completion of the sale, the insider directly owned 219,275 shares in the company, valued at $1,067,869.25. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $12,595.45.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $1,820.20.

SOPHiA GENETICS Stock Down 0.3%

SOPHiA GENETICS stock traded down $0.01 during mid-day trading on Wednesday, hitting $4.89. The company had a trading volume of 64,929 shares, compared to its average volume of 188,371. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The stock’s 50 day moving average price is $4.78 and its two-hundred day moving average price is $4.68. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The company has a market capitalization of $334.64 million, a PE ratio of -9.58 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth $55,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth $54,000. Archon Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of SOPHiA GENETICS by 169.5% in the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock worth $388,000 after purchasing an additional 52,200 shares during the last quarter. Finally, Polen Capital Management LLC purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth $102,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Guggenheim boosted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research restated a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.